| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wound Healing | 25 | 2023 | 460 | 5.870 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 24 | 2025 | 399 | 4.050 |
Why?
|
| Interleukin-10 | 12 | 2023 | 174 | 4.020 |
Why?
|
| Biomedical Research | 13 | 2023 | 519 | 3.750 |
Why?
|
| Surgeons | 9 | 2023 | 257 | 2.900 |
Why?
|
| Hyaluronic Acid | 11 | 2021 | 96 | 2.720 |
Why?
|
| Cicatrix | 6 | 2023 | 124 | 2.590 |
Why?
|
| Lung | 19 | 2024 | 1497 | 1.980 |
Why?
|
| Fetus | 11 | 2025 | 584 | 1.960 |
Why?
|
| Skin | 8 | 2023 | 518 | 1.830 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2024 | 96 | 1.820 |
Why?
|
| Respiratory System Abnormalities | 8 | 2024 | 42 | 1.780 |
Why?
|
| Gene Transfer Techniques | 10 | 2015 | 354 | 1.700 |
Why?
|
| Fibroblasts | 5 | 2020 | 875 | 1.630 |
Why?
|
| Neovascularization, Physiologic | 8 | 2022 | 214 | 1.590 |
Why?
|
| Awards and Prizes | 3 | 2023 | 65 | 1.560 |
Why?
|
| Career Mobility | 3 | 2021 | 50 | 1.530 |
Why?
|
| Writing | 3 | 2021 | 62 | 1.520 |
Why?
|
| Extracorporeal Membrane Oxygenation | 8 | 2024 | 613 | 1.480 |
Why?
|
| Fetoscopy | 12 | 2024 | 447 | 1.450 |
Why?
|
| Wounds and Injuries | 6 | 2020 | 370 | 1.430 |
Why?
|
| Extracellular Matrix | 8 | 2020 | 236 | 1.410 |
Why?
|
| Ultrasonography, Prenatal | 17 | 2024 | 968 | 1.390 |
Why?
|
| Intestines | 3 | 2021 | 577 | 1.380 |
Why?
|
| Prenatal Diagnosis | 12 | 2024 | 597 | 1.300 |
Why?
|
| Trachea | 9 | 2024 | 202 | 1.250 |
Why?
|
| Fetal Development | 3 | 2015 | 132 | 1.180 |
Why?
|
| Mentors | 3 | 2021 | 149 | 1.160 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 260 | 1.150 |
Why?
|
| Pregnancy | 47 | 2025 | 7192 | 1.140 |
Why?
|
| Research Support as Topic | 2 | 2021 | 63 | 1.120 |
Why?
|
| Discrete Subaortic Stenosis | 2 | 2024 | 7 | 1.120 |
Why?
|
| Phenyl Ethers | 2 | 2024 | 9 | 1.120 |
Why?
|
| Infant, Newborn | 42 | 2024 | 8196 | 1.110 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2023 | 133 | 1.100 |
Why?
|
| Financing, Organized | 3 | 2022 | 19 | 1.080 |
Why?
|
| Genetic Therapy | 4 | 2015 | 687 | 1.060 |
Why?
|
| Hypertension, Pulmonary | 4 | 2024 | 438 | 1.010 |
Why?
|
| Gestational Age | 10 | 2024 | 1160 | 0.990 |
Why?
|
| Humans | 109 | 2025 | 125035 | 0.950 |
Why?
|
| Bioprinting | 1 | 2024 | 11 | 0.930 |
Why?
|
| Spheroids, Cellular | 1 | 2024 | 57 | 0.920 |
Why?
|
| Hyaluronoglucosaminidase | 2 | 2021 | 26 | 0.910 |
Why?
|
| Gastroschisis | 2 | 2021 | 54 | 0.900 |
Why?
|
| General Surgery | 3 | 2019 | 206 | 0.890 |
Why?
|
| Wound Infection | 4 | 2022 | 53 | 0.890 |
Why?
|
| Pediatrics | 4 | 2019 | 1149 | 0.880 |
Why?
|
| Hydrops Fetalis | 3 | 2020 | 74 | 0.870 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 220 | 0.870 |
Why?
|
| Teratoma | 7 | 2024 | 120 | 0.860 |
Why?
|
| Fetal Therapies | 3 | 2018 | 80 | 0.860 |
Why?
|
| Kidney | 3 | 2021 | 1366 | 0.850 |
Why?
|
| Lung Diseases | 6 | 2023 | 383 | 0.850 |
Why?
|
| Dependovirus | 3 | 2013 | 128 | 0.840 |
Why?
|
| Bandages | 2 | 2020 | 53 | 0.820 |
Why?
|
| Genetic Vectors | 5 | 2013 | 937 | 0.820 |
Why?
|
| Cystic Fibrosis | 3 | 2012 | 256 | 0.800 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2015 | 341 | 0.800 |
Why?
|
| Obstetric Labor, Premature | 1 | 2023 | 85 | 0.790 |
Why?
|
| Cell Survival | 1 | 2024 | 812 | 0.780 |
Why?
|
| Retrospective Studies | 49 | 2025 | 16312 | 0.780 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 255 | 0.780 |
Why?
|
| Animals | 40 | 2024 | 34206 | 0.770 |
Why?
|
| Female | 71 | 2025 | 66718 | 0.760 |
Why?
|
| Actins | 1 | 2024 | 346 | 0.760 |
Why?
|
| Pulmonary Fibrosis | 2 | 2020 | 108 | 0.750 |
Why?
|
| Dermis | 1 | 2021 | 24 | 0.750 |
Why?
|
| Molecular Weight | 3 | 2021 | 390 | 0.750 |
Why?
|
| Abdominal Wall | 1 | 2021 | 32 | 0.740 |
Why?
|
| Budgets | 1 | 2021 | 17 | 0.740 |
Why?
|
| Mice | 31 | 2024 | 17621 | 0.730 |
Why?
|
| Adenoviridae | 6 | 2015 | 604 | 0.720 |
Why?
|
| Perinatal Care | 2 | 2022 | 67 | 0.700 |
Why?
|
| Mice, Inbred C57BL | 19 | 2023 | 4403 | 0.690 |
Why?
|
| Endothelial Progenitor Cells | 2 | 2022 | 11 | 0.690 |
Why?
|
| Skin Care | 1 | 2020 | 14 | 0.690 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2020 | 50 | 0.690 |
Why?
|
| Time-to-Treatment | 2 | 2018 | 186 | 0.670 |
Why?
|
| Gastrostomy | 2 | 2020 | 86 | 0.670 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 32 | 0.670 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 4390 | 0.670 |
Why?
|
| Debridement | 1 | 2020 | 89 | 0.660 |
Why?
|
| Emergency Treatment | 1 | 2020 | 84 | 0.650 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2022 | 409 | 0.650 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 472 | 0.640 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 298 | 0.640 |
Why?
|
| Science | 1 | 2019 | 33 | 0.630 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 200 | 0.630 |
Why?
|
| Heart Defects, Congenital | 4 | 2024 | 1821 | 0.610 |
Why?
|
| Academies and Institutes | 1 | 2019 | 83 | 0.610 |
Why?
|
| Fetal Diseases | 8 | 2024 | 456 | 0.600 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 196 | 0.600 |
Why?
|
| Herniorrhaphy | 1 | 2018 | 82 | 0.580 |
Why?
|
| Heart Transplantation | 1 | 2024 | 860 | 0.560 |
Why?
|
| Cells, Cultured | 8 | 2024 | 3051 | 0.560 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2019 | 478 | 0.540 |
Why?
|
| Sacrococcygeal Region | 4 | 2024 | 32 | 0.540 |
Why?
|
| Pandemics | 2 | 2021 | 1105 | 0.520 |
Why?
|
| Length of Stay | 8 | 2024 | 1307 | 0.510 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2015 | 137 | 0.510 |
Why?
|
| Angiopoietin-1 | 1 | 2015 | 7 | 0.500 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2015 | 21 | 0.500 |
Why?
|
| Pseudomonas Infections | 3 | 2022 | 114 | 0.480 |
Why?
|
| Placental Insufficiency | 1 | 2015 | 15 | 0.480 |
Why?
|
| Efficiency | 1 | 2015 | 63 | 0.460 |
Why?
|
| Myocardium | 1 | 2020 | 1016 | 0.460 |
Why?
|
| Prenatal Care | 5 | 2025 | 347 | 0.450 |
Why?
|
| Placenta | 3 | 2023 | 508 | 0.450 |
Why?
|
| Algorithms | 2 | 2022 | 1629 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1267 | 0.450 |
Why?
|
| Postoperative Complications | 4 | 2020 | 3069 | 0.440 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 140 | 0.440 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1718 | 0.430 |
Why?
|
| Skin Physiological Phenomena | 2 | 2013 | 20 | 0.430 |
Why?
|
| Palate | 1 | 2013 | 13 | 0.430 |
Why?
|
| Gallbladder | 1 | 2013 | 20 | 0.430 |
Why?
|
| Cholecystitis | 1 | 2013 | 20 | 0.430 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2013 | 5 | 0.420 |
Why?
|
| Mouth Mucosa | 1 | 2013 | 52 | 0.420 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 3 | 2022 | 20 | 0.410 |
Why?
|
| Infant | 19 | 2024 | 12462 | 0.410 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2011 | 43 | 0.410 |
Why?
|
| Fetal Growth Retardation | 1 | 2015 | 239 | 0.410 |
Why?
|
| United States | 9 | 2023 | 10908 | 0.410 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 97 | 0.410 |
Why?
|
| Saliva | 1 | 2013 | 114 | 0.400 |
Why?
|
| Pressure Ulcer | 1 | 2013 | 74 | 0.400 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 269 | 0.400 |
Why?
|
| Parvoviridae Infections | 1 | 2012 | 36 | 0.390 |
Why?
|
| Inflammation | 5 | 2024 | 1444 | 0.390 |
Why?
|
| Viral Proteins | 1 | 2014 | 347 | 0.390 |
Why?
|
| Cytokines | 4 | 2024 | 1285 | 0.390 |
Why?
|
| Viral Tropism | 1 | 2012 | 43 | 0.380 |
Why?
|
| Male | 32 | 2024 | 61436 | 0.380 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 173 | 0.370 |
Why?
|
| Research Personnel | 4 | 2022 | 117 | 0.370 |
Why?
|
| Exocrine Glands | 1 | 2011 | 8 | 0.360 |
Why?
|
| Airway Obstruction | 2 | 2023 | 165 | 0.350 |
Why?
|
| Pneumonectomy | 2 | 2018 | 143 | 0.350 |
Why?
|
| Endothelial Cells | 2 | 2024 | 522 | 0.340 |
Why?
|
| Child Development | 1 | 2013 | 266 | 0.340 |
Why?
|
| Macrophages | 3 | 2024 | 620 | 0.340 |
Why?
|
| Keratinocytes | 3 | 2016 | 62 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 3570 | 0.330 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 243 | 0.330 |
Why?
|
| Hymecromone | 2 | 2021 | 5 | 0.330 |
Why?
|
| Treatment Outcome | 16 | 2024 | 12382 | 0.330 |
Why?
|
| Vagina | 2 | 2020 | 185 | 0.300 |
Why?
|
| Echocardiography | 3 | 2019 | 1052 | 0.300 |
Why?
|
| Signal Transduction | 2 | 2020 | 4531 | 0.300 |
Why?
|
| Pelvic Neoplasms | 2 | 2022 | 21 | 0.300 |
Why?
|
| Spinal Neoplasms | 2 | 2022 | 57 | 0.290 |
Why?
|
| Clinical Competence | 1 | 2015 | 1003 | 0.290 |
Why?
|
| Quality Improvement | 1 | 2013 | 642 | 0.280 |
Why?
|
| Immune Tolerance | 2 | 2019 | 144 | 0.280 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2024 | 26 | 0.270 |
Why?
|
| Stress, Mechanical | 2 | 2024 | 173 | 0.270 |
Why?
|
| Cell Movement | 3 | 2015 | 846 | 0.260 |
Why?
|
| Organ Culture Techniques | 3 | 2014 | 156 | 0.260 |
Why?
|
| Mice, SCID | 2 | 2021 | 565 | 0.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 824 | 0.250 |
Why?
|
| Hospitals, Pediatric | 3 | 2024 | 760 | 0.240 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 282 | 0.240 |
Why?
|
| Alginates | 1 | 2024 | 18 | 0.240 |
Why?
|
| Poloxamer | 1 | 2024 | 12 | 0.240 |
Why?
|
| Porosity | 1 | 2024 | 38 | 0.230 |
Why?
|
| Heart | 2 | 2023 | 728 | 0.230 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 18 | 0.230 |
Why?
|
| Monitoring, Intraoperative | 1 | 2005 | 133 | 0.230 |
Why?
|
| Internship and Residency | 1 | 2015 | 1181 | 0.230 |
Why?
|
| Bronchi | 1 | 2005 | 97 | 0.230 |
Why?
|
| Child | 14 | 2022 | 24356 | 0.230 |
Why?
|
| Lymphatic Abnormalities | 1 | 2024 | 34 | 0.230 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 2168 | 0.220 |
Why?
|
| Organ Size | 5 | 2019 | 436 | 0.220 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2022 | 164 | 0.220 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 171 | 0.220 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 69 | 0.220 |
Why?
|
| Documentation | 1 | 2025 | 113 | 0.220 |
Why?
|
| Referral and Consultation | 2 | 2025 | 542 | 0.220 |
Why?
|
| LIM Domain Proteins | 1 | 2023 | 60 | 0.210 |
Why?
|
| Adolescent | 10 | 2022 | 19328 | 0.210 |
Why?
|
| Endocardium | 1 | 2023 | 51 | 0.210 |
Why?
|
| Survival Rate | 6 | 2019 | 2057 | 0.210 |
Why?
|
| Amniotic Band Syndrome | 1 | 2003 | 24 | 0.210 |
Why?
|
| Academic Success | 1 | 2023 | 19 | 0.210 |
Why?
|
| Biofilms | 2 | 2022 | 87 | 0.200 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2024 | 149 | 0.200 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2024 | 216 | 0.200 |
Why?
|
| Inovirus | 1 | 2022 | 2 | 0.200 |
Why?
|
| Hysterotomy | 2 | 2021 | 126 | 0.200 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2024 | 313 | 0.200 |
Why?
|
| Balloon Occlusion | 1 | 2022 | 47 | 0.200 |
Why?
|
| Limb Salvage | 1 | 2003 | 133 | 0.200 |
Why?
|
| Hydronephrosis | 2 | 2013 | 35 | 0.200 |
Why?
|
| Cohort Studies | 7 | 2021 | 4812 | 0.190 |
Why?
|
| Infant, Premature, Diseases | 1 | 2024 | 244 | 0.190 |
Why?
|
| Mice, Knockout | 3 | 2015 | 3741 | 0.190 |
Why?
|
| Congenital Abnormalities | 1 | 2025 | 255 | 0.190 |
Why?
|
| Transduction, Genetic | 2 | 2013 | 288 | 0.190 |
Why?
|
| Neck | 2 | 2024 | 135 | 0.190 |
Why?
|
| Fibrosis | 2 | 2021 | 434 | 0.190 |
Why?
|
| Polyhydramnios | 1 | 2021 | 56 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 458 | 0.180 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 3728 | 0.180 |
Why?
|
| Infant Mortality | 2 | 2020 | 173 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 5 | 1 | 2021 | 4 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2022 | 3455 | 0.180 |
Why?
|
| Cerebrospinal Fluid Leak | 2 | 2020 | 43 | 0.180 |
Why?
|
| Hemodynamics | 2 | 2022 | 850 | 0.180 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 218 | 0.180 |
Why?
|
| Prognosis | 6 | 2024 | 4630 | 0.180 |
Why?
|
| Child, Preschool | 7 | 2022 | 13984 | 0.180 |
Why?
|
| Graft Rejection | 1 | 2024 | 589 | 0.170 |
Why?
|
| Patient Selection | 2 | 2021 | 699 | 0.170 |
Why?
|
| Wound Closure Techniques | 1 | 2020 | 23 | 0.170 |
Why?
|
| Ointments | 1 | 2020 | 13 | 0.170 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 186 | 0.170 |
Why?
|
| Surgical Wound | 1 | 2020 | 23 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 558 | 0.170 |
Why?
|
| Simulation Training | 1 | 2022 | 137 | 0.170 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 53 | 0.170 |
Why?
|
| Animals, Newborn | 1 | 2024 | 1016 | 0.170 |
Why?
|
| Muscle Proteins | 1 | 2023 | 417 | 0.170 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 302 | 0.170 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2020 | 18 | 0.170 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 235 | 0.170 |
Why?
|
| Organ Specificity | 1 | 2021 | 429 | 0.170 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 107 | 0.170 |
Why?
|
| Multigene Family | 1 | 2021 | 299 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 1696 | 0.170 |
Why?
|
| Edema | 4 | 2023 | 136 | 0.160 |
Why?
|
| Abdomen | 1 | 2020 | 127 | 0.160 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 258 | 0.160 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2021 | 141 | 0.160 |
Why?
|
| Pseudomonas Phages | 1 | 2019 | 9 | 0.160 |
Why?
|
| Uterus | 1 | 2003 | 569 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2100 | 0.150 |
Why?
|
| Infant, Premature | 1 | 2024 | 817 | 0.150 |
Why?
|
| Adult | 14 | 2025 | 29624 | 0.150 |
Why?
|
| Adaptation, Physiological | 2 | 2013 | 270 | 0.150 |
Why?
|
| Bleomycin | 1 | 2019 | 153 | 0.150 |
Why?
|
| Hydrogels | 1 | 2019 | 84 | 0.150 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 873 | 0.150 |
Why?
|
| Phagocytosis | 1 | 2019 | 171 | 0.150 |
Why?
|
| Gynecology | 1 | 2019 | 123 | 0.150 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2011 | 15 | 0.150 |
Why?
|
| Regeneration | 1 | 2020 | 212 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2025 | 721 | 0.140 |
Why?
|
| Liver | 4 | 2022 | 1743 | 0.140 |
Why?
|
| Estrogens | 1 | 2020 | 504 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 131 | 0.140 |
Why?
|
| Meningomyelocele | 1 | 2021 | 250 | 0.140 |
Why?
|
| Oropharynx | 1 | 2017 | 34 | 0.140 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 647 | 0.140 |
Why?
|
| Time Factors | 3 | 2024 | 6327 | 0.140 |
Why?
|
| Faculty, Medical | 1 | 2020 | 262 | 0.140 |
Why?
|
| Career Choice | 1 | 2019 | 148 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 160 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2022 | 768 | 0.140 |
Why?
|
| Financing, Government | 1 | 2017 | 30 | 0.140 |
Why?
|
| Insufflation | 1 | 2017 | 20 | 0.140 |
Why?
|
| Disease Management | 1 | 2021 | 525 | 0.140 |
Why?
|
| Glycosaminoglycans | 2 | 2021 | 33 | 0.140 |
Why?
|
| Transcriptome | 1 | 2023 | 951 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 183 | 0.140 |
Why?
|
| Flow Cytometry | 3 | 2015 | 794 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2308 | 0.130 |
Why?
|
| Neural Tube Defects | 1 | 2020 | 356 | 0.130 |
Why?
|
| Ultrasonography | 3 | 2013 | 940 | 0.130 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2016 | 35 | 0.130 |
Why?
|
| Telemedicine | 1 | 2022 | 435 | 0.130 |
Why?
|
| Anxiety | 1 | 2023 | 960 | 0.130 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 278 | 0.130 |
Why?
|
| Forecasting | 1 | 2017 | 352 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 337 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 93 | 0.120 |
Why?
|
| Survivors | 1 | 2018 | 339 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5169 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2906 | 0.120 |
Why?
|
| Biomarkers | 2 | 2015 | 3081 | 0.120 |
Why?
|
| Thoracic Cavity | 1 | 2014 | 2 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 664 | 0.120 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 93 | 0.120 |
Why?
|
| Lung Volume Measurements | 3 | 2023 | 75 | 0.120 |
Why?
|
| Allergens | 1 | 2017 | 252 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2020 | 493 | 0.110 |
Why?
|
| Cell Nucleus | 2 | 2017 | 680 | 0.110 |
Why?
|
| Depression | 1 | 2023 | 1236 | 0.110 |
Why?
|
| Rabbits | 1 | 2015 | 718 | 0.110 |
Why?
|
| Octreotide | 1 | 2013 | 22 | 0.110 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 62 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 517 | 0.110 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 979 | 0.110 |
Why?
|
| Chylothorax | 1 | 2013 | 27 | 0.110 |
Why?
|
| Submandibular Gland | 1 | 2013 | 6 | 0.110 |
Why?
|
| Probability | 2 | 2024 | 321 | 0.110 |
Why?
|
| Interleukin-10 Receptor alpha Subunit | 1 | 2013 | 5 | 0.110 |
Why?
|
| Critical Illness | 1 | 2018 | 601 | 0.100 |
Why?
|
| Spinal Dysraphism | 1 | 2017 | 270 | 0.100 |
Why?
|
| Ovarian Diseases | 1 | 2013 | 28 | 0.100 |
Why?
|
| Torsion Abnormality | 1 | 2013 | 35 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 79 | 0.100 |
Why?
|
| Pleural Effusion | 1 | 2013 | 102 | 0.100 |
Why?
|
| Fetal Stem Cells | 1 | 2012 | 4 | 0.100 |
Why?
|
| Young Adult | 6 | 2021 | 9042 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 230 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 769 | 0.100 |
Why?
|
| Quality of Life | 2 | 2022 | 1939 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2521 | 0.100 |
Why?
|
| Growth Substances | 1 | 2012 | 113 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 219 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 389 | 0.090 |
Why?
|
| Mice, Inbred CFTR | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cecal Diseases | 1 | 2010 | 6 | 0.090 |
Why?
|
| Appendix | 1 | 2010 | 15 | 0.090 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2011 | 46 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 243 | 0.090 |
Why?
|
| Hemangioblasts | 1 | 2010 | 2 | 0.090 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2010 | 15 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 36 | 0.090 |
Why?
|
| Postnatal Care | 3 | 2019 | 51 | 0.090 |
Why?
|
| Immunity | 2 | 2022 | 191 | 0.090 |
Why?
|
| Fetal Death | 2 | 2013 | 112 | 0.080 |
Why?
|
| Ohio | 3 | 2014 | 86 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2013 | 391 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2010 | 1020 | 0.080 |
Why?
|
| Wounds, Penetrating | 1 | 2010 | 141 | 0.080 |
Why?
|
| Hyaluronan Receptors | 2 | 2021 | 66 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 959 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2013 | 1632 | 0.080 |
Why?
|
| Urogenital Abnormalities | 1 | 2011 | 154 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 946 | 0.080 |
Why?
|
| Apoptosis | 1 | 2015 | 1803 | 0.070 |
Why?
|
| Hernia, Umbilical | 1 | 2008 | 42 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 503 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 2786 | 0.070 |
Why?
|
| Drainage | 1 | 2010 | 259 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 1002 | 0.070 |
Why?
|
| Texas | 3 | 2024 | 3586 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2013 | 1179 | 0.070 |
Why?
|
| Hernia, Diaphragmatic | 3 | 2013 | 98 | 0.070 |
Why?
|
| Salivary Glands | 1 | 2007 | 33 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2010 | 283 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2019 | 119 | 0.070 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2019 | 165 | 0.070 |
Why?
|
| Ileum | 1 | 2007 | 133 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 294 | 0.070 |
Why?
|
| Dendritic Cells | 2 | 2021 | 414 | 0.070 |
Why?
|
| Physicians | 1 | 2013 | 586 | 0.070 |
Why?
|
| Pregnancy Outcome | 3 | 2017 | 591 | 0.060 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2005 | 7 | 0.060 |
Why?
|
| Anesthesia, Epidural | 1 | 2005 | 14 | 0.060 |
Why?
|
| Granulation Tissue | 1 | 2005 | 13 | 0.060 |
Why?
|
| Fentanyl | 1 | 2005 | 46 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 2 | 2017 | 113 | 0.060 |
Why?
|
| Streptozocin | 1 | 2004 | 24 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 3137 | 0.060 |
Why?
|
| Sclerotherapy | 1 | 2024 | 40 | 0.060 |
Why?
|
| Airway Management | 1 | 2024 | 62 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2024 | 33 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2005 | 357 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 282 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 231 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3424 | 0.050 |
Why?
|
| Lentivirus | 1 | 2004 | 81 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 384 | 0.050 |
Why?
|
| Wrist | 1 | 2003 | 24 | 0.050 |
Why?
|
| Models, Animal | 2 | 2020 | 464 | 0.050 |
Why?
|
| Sirolimus | 1 | 2024 | 227 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 318 | 0.050 |
Why?
|
| Cell Separation | 1 | 2023 | 228 | 0.050 |
Why?
|
| Pseudomonas | 1 | 2022 | 11 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2022 | 55 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 183 | 0.050 |
Why?
|
| Universities | 1 | 2023 | 125 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2022 | 81 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 779 | 0.050 |
Why?
|
| Propylene Glycol | 1 | 2021 | 9 | 0.050 |
Why?
|
| Antithrombin III | 1 | 2021 | 25 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 190 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 2054 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2021 | 67 | 0.050 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2021 | 6 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 66 | 0.050 |
Why?
|
| Disaccharides | 1 | 2021 | 14 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 93 | 0.050 |
Why?
|
| Thorax | 1 | 2021 | 73 | 0.050 |
Why?
|
| Intubation, Intratracheal | 1 | 2024 | 286 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 242 | 0.050 |
Why?
|
| Patient Preference | 1 | 2022 | 118 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 257 | 0.050 |
Why?
|
| Mast Cells | 1 | 2021 | 78 | 0.040 |
Why?
|
| Diaphragm | 1 | 2021 | 98 | 0.040 |
Why?
|
| Immune System | 1 | 2021 | 89 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 90 | 0.040 |
Why?
|
| Water | 1 | 2021 | 186 | 0.040 |
Why?
|
| Counseling | 1 | 2022 | 218 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 6153 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 359 | 0.040 |
Why?
|
| Ethanol | 1 | 2021 | 163 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2021 | 78 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2023 | 527 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 385 | 0.040 |
Why?
|
| Heparin | 1 | 2021 | 224 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 277 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2019 | 32 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 354 | 0.040 |
Why?
|
| Swine | 1 | 2023 | 1207 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 433 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2022 | 492 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1025 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 249 | 0.040 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2019 | 18 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 221 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 606 | 0.040 |
Why?
|
| Middle Aged | 2 | 2021 | 26922 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2019 | 45 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 557 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1328 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 39 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 373 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 534 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2013 | 1504 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 1332 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 469 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 457 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 125 | 0.040 |
Why?
|
| Psychometrics | 1 | 2022 | 674 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2020 | 242 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1420 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 2817 | 0.040 |
Why?
|
| Endoscopy | 1 | 2019 | 281 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2021 | 441 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2019 | 215 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 650 | 0.030 |
Why?
|
| Perinatal Mortality | 1 | 2017 | 43 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 355 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2017 | 68 | 0.030 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 54 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 593 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 458 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2017 | 55 | 0.030 |
Why?
|
| Half-Life | 1 | 2016 | 158 | 0.030 |
Why?
|
| Biological Availability | 1 | 2016 | 137 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 682 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 368 | 0.030 |
Why?
|
| Stents | 1 | 2022 | 888 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 307 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2017 | 1895 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 264 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2889 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 459 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 1270 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 854 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 107 | 0.030 |
Why?
|
| Thoracostomy | 1 | 2013 | 26 | 0.030 |
Why?
|
| Chest Tubes | 1 | 2013 | 35 | 0.030 |
Why?
|
| Cardiac Output, High | 1 | 2013 | 2 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 2425 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 323 | 0.030 |
Why?
|
| Nausea | 1 | 2013 | 86 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 569 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 1155 | 0.030 |
Why?
|
| Vomiting | 1 | 2013 | 105 | 0.020 |
Why?
|
| Risk Factors | 2 | 2019 | 10282 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2013 | 111 | 0.020 |
Why?
|
| Tidal Volume | 1 | 2011 | 38 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 2397 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 820 | 0.020 |
Why?
|
| Urinary Tract | 1 | 2011 | 60 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 309 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 15 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 14 | 0.020 |
Why?
|
| Ovary | 1 | 2013 | 380 | 0.020 |
Why?
|
| Hospital Records | 1 | 2010 | 8 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 56 | 0.020 |
Why?
|
| Soft Tissue Injuries | 1 | 2010 | 11 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1239 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 308 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 73 | 0.020 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 43 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 435 | 0.020 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 85 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 285 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2010 | 180 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 2061 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 698 | 0.020 |
Why?
|
| Microvilli | 1 | 2007 | 71 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1290 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2007 | 244 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 258 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 122 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 1110 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 257 | 0.020 |
Why?
|
| Transgenes | 1 | 2007 | 336 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1532 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 1120 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 464 | 0.020 |
Why?
|
| Tobramycin | 1 | 2005 | 23 | 0.020 |
Why?
|
| Bupivacaine | 1 | 2005 | 24 | 0.020 |
Why?
|
| Aged | 1 | 2003 | 19859 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2005 | 139 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2005 | 66 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 1701 | 0.010 |
Why?
|
| Thoracotomy | 1 | 2005 | 111 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2005 | 218 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2005 | 84 | 0.010 |
Why?
|
| Analgesics | 1 | 2005 | 127 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 267 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2820 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2005 | 279 | 0.010 |
Why?
|
| Pain | 1 | 2005 | 450 | 0.010 |
Why?
|